AU733417B2 - Vitronectin receptor antagonists - Google Patents

Vitronectin receptor antagonists Download PDF

Info

Publication number
AU733417B2
AU733417B2 AU47462/97A AU4746297A AU733417B2 AU 733417 B2 AU733417 B2 AU 733417B2 AU 47462/97 A AU47462/97 A AU 47462/97A AU 4746297 A AU4746297 A AU 4746297A AU 733417 B2 AU733417 B2 AU 733417B2
Authority
AU
Australia
Prior art keywords
oxo
benzazepine
tetrahydro
acetic acid
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU47462/97A
Other languages
English (en)
Other versions
AU4746297A (en
Inventor
James Francis Callahan
Russell Donovan Cousins
Richard Mccullock Keenan
Chet Kwon
William Henry Miller
Irene Nijole Uzinkas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU4746297A publication Critical patent/AU4746297A/en
Application granted granted Critical
Publication of AU733417B2 publication Critical patent/AU733417B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU47462/97A 1996-10-02 1997-10-01 Vitronectin receptor antagonists Ceased AU733417B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US60/027320 1996-10-02
US4377697P 1997-04-11 1997-04-11
US60/043776 1997-04-11
PCT/US1997/018001 WO1998014192A1 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Publications (2)

Publication Number Publication Date
AU4746297A AU4746297A (en) 1998-04-24
AU733417B2 true AU733417B2 (en) 2001-05-17

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47462/97A Ceased AU733417B2 (en) 1996-10-02 1997-10-01 Vitronectin receptor antagonists

Country Status (36)

Country Link
EP (1) EP0957917B1 (https=)
JP (2) JP4491072B2 (https=)
KR (1) KR100589578B1 (https=)
CN (1) CN1114403C (https=)
AP (1) AP1463A (https=)
AR (1) AR008878A1 (https=)
AT (1) ATE312089T1 (https=)
AU (1) AU733417B2 (https=)
BG (1) BG64581B1 (https=)
BR (1) BR9712248B1 (https=)
CA (1) CA2267224C (https=)
CO (1) CO4900046A1 (https=)
CY (1) CY2576B1 (https=)
CZ (1) CZ299076B6 (https=)
DE (1) DE69734833T2 (https=)
DK (1) DK0957917T3 (https=)
DZ (1) DZ2320A1 (https=)
EA (1) EA002419B1 (https=)
ES (1) ES2252775T3 (https=)
HU (1) HU229221B1 (https=)
ID (1) ID19623A (https=)
IL (1) IL129243A (https=)
MA (1) MA24361A1 (https=)
MY (1) MY137606A (https=)
NO (1) NO320194B1 (https=)
NZ (1) NZ334953A (https=)
PE (1) PE10499A1 (https=)
PL (1) PL190859B1 (https=)
RO (1) RO119881B1 (https=)
SA (1) SA98180936B1 (https=)
SK (1) SK285029B6 (https=)
TR (1) TR199900737T2 (https=)
TW (1) TW487702B (https=)
UA (1) UA60311C2 (https=)
UY (2) UY24735A1 (https=)
WO (1) WO1998014192A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
TR200000786T2 (tr) * 1997-09-24 2000-08-21 Smithkline Beecham Corporation Vitronektin reseptör antagonisti
CN1273529A (zh) * 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
CA2358855A1 (en) * 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
EP2359831A3 (en) * 1999-04-30 2012-02-01 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
JP2003506452A (ja) * 1999-08-06 2003-02-18 スミスクライン・ビーチャム・コーポレイション 発作の治療に有用なビトロネクチン受容体アンタゴニスト
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
DE60230404D1 (https=) * 2001-04-10 2009-01-29 Smithkline Beecham Corp
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
WO2002090325A2 (en) * 2001-05-03 2002-11-14 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
ES2671522T3 (es) 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TW200635902A (en) * 2004-12-21 2006-10-16 Smithkline Beecham Corp Methods and formulations
HRP20100559T1 (hr) * 2005-11-29 2010-11-30 Glaxosmithkline Llc Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule
ES2457822T3 (es) 2007-11-08 2014-04-29 The General Hospital Corporation Procedimientos y composiciones de tratamiento de enfermedades proteinúricas
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
EP2257538B1 (en) * 2008-03-06 2016-04-27 GlaxoSmithKline LLC Process for the preparation of benzodiazepine derivatives
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
CN102427816A (zh) * 2009-03-30 2012-04-25 宇部兴产株式会社 用于治疗或预防眼病的药物组合物
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
CA2767409C (en) 2009-07-24 2018-10-30 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
CA3172692C (en) * 2020-04-26 2024-05-14 Jiangsu Nhwa Pharmaceutical Co., Ltd 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ314922A (en) * 1992-12-21 1998-11-25 Smithkline Beecham Corp Benzodiazepinones; nitrogen containing heterocyclic intermediates and pharmaceutical compositions
EP0767792A4 (en) * 1994-06-29 2002-11-20 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000574A1 (en) * 1994-06-29 1996-01-11 Smithkline Beecham Corporation Vitronectin receptor antagonists

Also Published As

Publication number Publication date
BR9712248B1 (pt) 2010-06-29
HK1023730A1 (en) 2000-09-22
CN1238689A (zh) 1999-12-15
CZ299076B6 (cs) 2008-04-16
PL332674A1 (en) 1999-09-27
HUP9903769A3 (en) 2000-07-28
SK42599A3 (en) 1999-12-10
HUP9903769A2 (hu) 2000-03-28
KR100589578B1 (ko) 2006-06-15
UY24735A1 (es) 1998-03-30
DZ2320A1 (fr) 2002-12-28
NO320194B1 (no) 2005-11-14
JP4491072B2 (ja) 2010-06-30
WO1998014192A1 (en) 1998-04-09
BR9712248A (pt) 1999-08-24
SK285029B6 (sk) 2006-04-06
SA98180936B1 (ar) 2006-05-30
PE10499A1 (es) 1999-03-27
CA2267224C (en) 2007-03-13
KR20000048816A (ko) 2000-07-25
PL190859B1 (pl) 2006-02-28
AR008878A1 (es) 2000-02-23
MA24361A1 (fr) 1998-07-01
DK0957917T3 (da) 2006-04-18
TR199900737T2 (xx) 1999-07-21
AP9901493A0 (en) 1999-03-31
CZ113299A3 (cs) 2000-03-15
CO4900046A1 (es) 2000-03-27
DE69734833D1 (de) 2006-01-12
IL129243A (en) 2004-07-25
EP0957917A4 (en) 2002-05-15
NO991590L (no) 1999-05-31
RO119881B1 (ro) 2005-05-30
AU4746297A (en) 1998-04-24
HU229221B1 (en) 2013-09-30
ATE312089T1 (de) 2005-12-15
CY2576B1 (en) 2008-07-02
NZ334953A (en) 2000-01-28
JP2010006838A (ja) 2010-01-14
TW487702B (en) 2002-05-21
JP2001501936A (ja) 2001-02-13
IL129243A0 (en) 2000-02-17
EA199900356A1 (ru) 2000-02-28
EP0957917A1 (en) 1999-11-24
UA60311C2 (uk) 2003-10-15
UY24935A1 (es) 2001-07-31
CN1114403C (zh) 2003-07-16
BG64581B1 (bg) 2005-08-31
CA2267224A1 (en) 1998-04-09
BG103299A (en) 2000-01-31
NO991590D0 (no) 1999-03-31
MY137606A (en) 2009-02-27
EA002419B1 (ru) 2002-04-25
AP1463A (en) 2005-09-10
ES2252775T3 (es) 2006-05-16
EP0957917B1 (en) 2005-12-07
ID19623A (id) 1998-07-23
DE69734833T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
AU733417B2 (en) Vitronectin receptor antagonists
US6239138B1 (en) Vitronectin receptor antagonist
AU738433B2 (en) Vitronectin receptor antagonists
CA2303846A1 (en) Vitronectin receptor antagonist
CA2304000A1 (en) Vitronectin receptor antagonist
US6825188B2 (en) Vitronectin receptor antagonists
US6458814B1 (en) Vitronectin receptor antagonists
US20020019387A1 (en) Vitronectin receptor antagonist
US6576643B2 (en) Vitronectin receptor antagonists
US20020040136A1 (en) Vitronectin receptor antagonist
HK1023730B (en) Vitronectin receptor antagonists

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)